PMID- 27928427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1756-2872 (Print)
IS  - 1756-2880 (Electronic)
IS  - 1756-2872 (Linking)
VI  - 8
IP  - 4
DP  - 2016 Aug
TI  - Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and 
      experience.
PG  - 249-256
AB  - Erectile dysfunction (ED) is a very common disorder with a deep impact on quality 
      of life on both patients and partners. Several options are available for treating 
      ED: oral pharmacotherapy with phosphodiesterase 5 (PDE5) inhibitors currently 
      represents the first-line option for many patients with ED. Alprostadil, a 
      prostaglandin, has been marketed for many years as a urethral stick and an 
      intracavernous injection for the treatment of ED. It is now available in the form 
      of a cream (Vitaros/Virirec), a noninvasive treatment which combines an active 
      drug (alprostadil, a synthetic prostaglandin E1) with a skin enhancer improving 
      its local absorption directly at the site of action. Alprostadil has a favourable 
      pharmacodynamic profile and is poorly absorbed in systemic circulation, which 
      makes it suitable in a lot of circumstances and results in a reduced risk of 
      adverse effects (AEs). Systemic AEs are reported in only 3% of the treated 
      population. Clinical efficacy has been demonstrated in both phase II and III 
      trials, showing a global efficacy up to 83% with the 300 mug dose in patients with 
      severe ED, significantly better than placebo. Its fast onset of action and lack 
      of interactions with other drugs makes alprostadil cream a possible first-line 
      therapeutic option for some patients with ED: individuals who are reluctant to 
      take systemic treatments or have AEs, patients who do not respond, cannot 
      tolerate, or do not accept PDE5 inhibitor therapy, and patients treated with 
      nitrates. Therefore, this new treatment for ED can be offered to patients and 
      could help address the needs unmet by other treatments.
FAU - Cuzin, Beatrice
AU  - Cuzin B
AD  - Department of Urology and Transplantation, E Herriot University Hospital, 69437 
      Lyon Cedex, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160503
PL  - England
TA  - Ther Adv Urol
JT  - Therapeutic advances in urology
JID - 101487328
PMC - PMC5131739
OTO - NOTNLM
OT  - alprostadil cream
OT  - clinical evidence
OT  - real life
COIS- The author declares that there is no conflict of interest.
EDAT- 2016/12/09 06:00
MHDA- 2016/12/09 06:01
PMCR- 2016/08/01
CRDT- 2016/12/09 06:00
PHST- 2016/12/09 06:00 [entrez]
PHST- 2016/12/09 06:00 [pubmed]
PHST- 2016/12/09 06:01 [medline]
PHST- 2016/08/01 00:00 [pmc-release]
AID - 10.1177_1756287216644116 [pii]
AID - 10.1177/1756287216644116 [doi]
PST - ppublish
SO  - Ther Adv Urol. 2016 Aug;8(4):249-256. doi: 10.1177/1756287216644116. Epub 2016 
      May 3.